TIAN Mei elected President of World Molecular Imaging Society

World Molecular Imaging Society(WMIS)has elected Prof. TIAN Mei, MD., PhD., FWMIS, to serve as its President for the term beginning in the autumn of 2021. She has taken office as President-elect since this month. This is the first time that the Chinese expert has been named as the WMIS president.

TIAN Mei focuses her current research on molecular imaging of central nerve system (CNS) diseases & psychiatric disorders, imaging-based stem cell therapy for stroke, development of novel imaging strategies for a better understanding of underlying mechanism of brain. She has led her team to develop precision PET imaging approach on pediatric epilepsy and MRI-negative pre-operative epilepsy. Her team has also developed big data-based smart diagnosis for neuro-psychiatric disorders and novel molecular imaging agents or smart probes for precision theranostics. She is the recipient of many scientific awards for her extraordinary accomplishments, including the Chinese Young Women in Science Award, National Distinguished Young Scientist Award, International Young Investigator Grant (RSNA), and Asia and Oceania Distinguished Young Investigator Award (JSNM).

“It is my greatest honor to be named President of WMIS and serve our members of the society,” said TIAN Mei. “As I look towards the future, I envision WMIS will continue to keep its leadership position in the cross-scale and multi-disciplinary biomedical fields, while promoting the implementation of new innovative initiatives to keep pace with the ever-evolving research landscape towards the future medicine.”

Molecular imaging is a growing biomedical research discipline that enables the visualization, characterization and qualification of biologic processes taking place at the cellular and subcellular levels within intact living subjects, including patients. Established in 2011 by integrating the Academy of Molecular Imaging and the Society for Molecular Imaging, WMIS is an international organization dedicated to driving innovation of multimodal molecular imaging as a critical tool for discovery, preclinical, translational and clinical studies.

Comments are closed.